Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Zydus Cadila wins DCGI...

    Zydus Cadila wins DCGI nod for marketing rabies drug Twinrab

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-09-03T10:00:35+05:30  |  Updated On 17 Aug 2021 12:57 PM IST

    "The novel biologic which will be marketed under the brand name, Twinrab, is indicated in combination with rabies vaccine for rabies post-exposure prophylaxis," Zydus Cadila said in a statement.


    New Delhi: Zydus Cadila on Tuesday said it has received marketing authorisation for Twinrab, used for treating rabies, from the Drug Controller General of India (DCGI).


    "The novel biologic which will be marketed under the brand name, Twinrab, is indicated in combination with rabies vaccine for rabies post-exposure prophylaxis," Zydus Cadila said in a statement.


    Rabies, a viral disease which gets transmitted through the bite of a rabid animal, affects the central nervous system.


    Zydus said in 2008, it had entered into an agreement with the World Health Organization (WHO) to explore opportunities in the development of a cocktail of monoclonal antibodies for the treatment of rabies.


    Read Also: Zydus Cadila begins phase 2 trial for Saroglitazar Mg to treat NAFLD in women with PCOS


    "The use of rabies monoclonal antibodies could emerge as an innovative therapy and form a potent alternative to current blood-derived rabies immunoglobulins (RIG's) produced by vaccinating horses (ERIG) or humans (HRlG)," the company added.


    Zydus said it currently also manufactures and markets the rabies vaccine — VaxiRab which is a WHO pre-qualified vaccine.


    Read Also: Zydus Cadila gets USFDA nod for Ranolazine Extended-Release tablets to treat chronic angina

    DCGI nodDrug Controller General of IndiaERIGHRlGimmunoglobulinsmonoclonal antibodiesnervous systempharmapharma companypharma newspharma news indiaprophylaxisrabies drugTwinrabvaccinating horsesvaccinationVaxiRabWHOWorld Health OrganizationZydus Cadila
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok